Primary tumors in 7(23.33%) NSCLC patients expressed weakly positive ERβ, 14(46.67%) primary tumor specimens were moderately positive for ERβ while the other 9(30%) specimens were strongly positive. The gene discussed is ESR2; the disease is non-small cell lung carcinoma.